# NEOGENOMICS INC (NEO) — capital_raise [announced]
Source: SEC API (secapi.ai) · situation sit_cbb721e944c362471c06 · retrieved 2026-08-11T16:12:47.500Z

## Overview
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services, offering comprehensive oncology-focused testing menus across the cancer continuum.

NeoGenomics completed a $316 million private offering of 0.75% convertible senior notes due 2032. As part of the capital structure refinancing, the company repurchased approximately $276 million aggregate principal amount of its existing 0.25% convertible senior notes due 2028 and entered into capped call transactions to reduce potential dilution upon conversion. The company also repurchased shares of common stock for an aggregate purchase price of $25 million.

## Terms
- Deal value: $316.0M · Consideration: mixed

## Key dates
- Announced 2026-07-28

## Timeline
- 2026-07-28 · 8-K (0001077183-26-000058): 8-K - NEOGENOMICS INC — *NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services, offering comprehensive oncology-focused testing menus across the cancer continuum.* NeoGenomics completed a $316 million private offering of 0.75% convertible senior notes due 2032. As part of the capital structure refinancing, the company repurchased approximately $276 million aggregate principal amount of its existing 0.25% convertible senior notes due 2028 and entered into capped call transactions to reduce potential dilution upon conversion. The company also repurchased shares of common stock for an aggregate purchase price of $25 million.
  https://www.sec.gov/Archives/edgar/data/1077183/0001077183-26-000058.txt

## Citations
- 0001077183-26-000058 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000107718326000058